Oslo, 13 August 2021 - Navamedic ASA (OSE: NAVA) grew revenues by 56.7% in the
second quarter of 2021 compared to the same quarter last year. The company
reported revenues of NOK 66.0 million in the second quarter of 2021 with an
EBITDA of NOK 4.3 million, driven by both new products, underlying growth and an
improved revenue mix. The company reiterates its mid- to long-term ambition of
building a NOK 500 million company.

"We continue to deliver rapid growth for our specialty pharma product Mysimba
and consumer health products Alflorex and ThermaCare. In parallel, we expand our
product portfolio with important new products such as Cysticina and
PrecisionBiotics Zenflore, further strengthening our position in prioritized
areas like gastro, obesity and other lifestyle related issues, says Kathrine
Gamborg Andreassen, Chief Executive Officer of Navamedic ASA, and continues.

"The performance of our key products and the addition of new products show the
quality of our platform, the strength of our team and expertise and our
execution power in sourcing. This will be key as we embark on the second half of
2021, following our plan for building a leading Nordic pharma company."

Revenues in the second quarter of 2021 were NOK 66.0 million (42.1 million in
the second quarter of 2020). The gross margin was 39.3% (34.8%), while the
EBITDA was NOK 4.3 million (-2.1). In the first half of 2021, revenues grew by
27.5% compared to the same period last year, up from NOK 97.8 million to NOK
124.7 million, while EBITDA was NOK 6.9 million, up from negative NOK 1.4
million in the same period last year. Navamedic will launch products in at least
one country in each launch window going forward. The company targets 20% annual
growth from 2021 and reiterates its mid- to long-term ambition of building a NOK
500 million company with strong gross margins and underlying profitability.

Navamedic will hold a presentation of the second quarter and first half 2021
financial results, Friday 13 August at 08.30 CET. The presentation will be held
at Sparebank 1 Markets in Olav V's gate 5 in Oslo as well as via webcast on
www.navamedic.com/investors/financial-results. Representatives from Navamedic
will be CEO Kathrine Gamborg Andreassen and CFO Lars Hjarrand.

EBITDA and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
attached second quarter and first half 2021 presentation on slide 20.

For further information, please contact:

Kathrine Gamborg Andreassen, CEO, Navamedic

Mobile: +47 951 78 680

E-mail: kathrine@navamedic.com

Lars Hjarrand, CFO, Navamedic

Mobile: +47 917 62 842

E-mail: lars.hjarrand@navamedic.com

Navamedic ASA is a Nordic pharma company and reliable provider of high-quality
products, delivered to hospitals and through pharmacies, meeting the specific
needs of patients and consumers by leveraging its highly scalable market access
platform, leading category competence and local knowledge. Navamedic is present
in all the Nordic countries, the Baltics and Benelux, with sales representation
in the UK and Greece. Navamedic is headquartered in Oslo, Norway, and listed on
the Oslo Stock Exchange (ticker: NAVA). For more information, please
visit www.navamedic.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.